Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Claudin-1 as a promoter of EMT in hepatocellular carcinoma

Oncogene volume 32, pages 4871–4872 (2013)Cite this article

Subjects

Abstract

Claudins are integral structural and functional components of apical cell adhesions (tight junctions). Loss of such adhesions has been associated with malignant transformation, a process most often accompanied by a concomitant loss of claudin expression. A growing body of evidence reveals the highly contextual upregulation of claudin expression in certain cancer types, and moreover their relevance in promoting cancer cell invasion and metastatic progression. In this issue of Oncogene, Suh et al. reported on claudin-1 expression in hepatocellular carcinoma (HCC), including its role as a promoter of the epithelial−to−mesenchymal transition via the c-Abl/Raf/Ras/ERK signaling pathway. Considering the limited therapeutic options in HCC, evaluation of its role as a target merits further investigation.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Roxburgh P, Evans TR . Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther 2008; 25: 1089–1104.

    Article  CAS  Google Scholar 

  2. Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS, Hwang SG et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 2013; 32: 1743–1868.

    Article  Google Scholar 

  3. Turksen K, Troy TC . Junctions gone bad: claudins and loss of the barrier in cancer. Biochim Biophys Acta 2011; 1816: 73–79.

    CAS  PubMed  Google Scholar 

  4. Singh AB, Sharma A, Dhawan P . Claudin family of proteins and cancer: an overview. J oncol 2010; 2010: 541957.

    Article  Google Scholar 

  5. Morin PJ . Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005; 65: 9603–9606.

    Article  CAS  Google Scholar 

  6. Myal Y, Leygue E, Blanchard AA . Claudin 1 in breast tumorigenesis: revelation of a possible novel ‘claudin high’ subset of breast cancers. J Biomed Biotechnol 2010; 2010: 956897.

    Article  Google Scholar 

  7. Tabaries S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J et al. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol 2012; 32: 2979–2991.

    Article  CAS  Google Scholar 

  8. Yoon CH, Kim MJ, Park MJ, Park IC, Hwang SG, An S et al. Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem 2010; 285: 226–233.

    Article  CAS  Google Scholar 

  9. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005; 115: 1765–1776.

    Article  CAS  Google Scholar 

  10. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G . Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3: 236–260.

    Article  Google Scholar 

  11. Suzuki H, Kondoh M, Takahashi A, Yagi K . Proof of concept for claudin-targeted drug development. Ann NY Acad Sci 2012; 1258: 65–70.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

JS and GG are supported by grants from Cancer Research UK, and Action against Cancer.

Author information

Authors and Affiliations

  1. Division of Surgery and Cancer, Imperial College London, London, UK

    J Stebbing, A Filipović & G Giamas

Authors
  1. J Stebbing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Filipović
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Giamas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Giamas.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stebbing, J., Filipović, A. & Giamas, G. Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene 32, 4871–4872 (2013). https://doi.org/10.1038/onc.2012.591

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2012.591

Keywords

This article is cited by

Search

Advanced search

Quick links